IP Verse

Bispecific Nanobodies - EP3049439

The patent EP3049439 was granted to Ablynx on Dec 25, 2019. The application was originally filed on Sep 26, 2014 under application number EP14777078A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3049439

ABLYNX
Application Number
EP14777078A
Filing Date
Sep 26, 2014
Status
Opposition Rejected
Sep 5, 2025
Grant Date
Dec 25, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOIBERG PSSep 25, 2020HOIBERG PSADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2007042289
INTERNATIONAL-SEARCH-REPORTWO2007066106
INTERNATIONAL-SEARCH-REPORTWO2009030285
INTERNATIONAL-SEARCH-REPORTWO2010037838
INTERNATIONAL-SEARCH-REPORTWO2012042026
INTERNATIONAL-SEARCH-REPORTWO2013064701
OPPOSITIONUS2010021473
OPPOSITIONWO2005117973
OPPOSITIONWO2006091209
OPPOSITIONWO2007042289
OPPOSITIONWO2012042026

Non-Patent Literature (NPL) Citations (13) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- ROB C. ROOVERS ET AL, "A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth", INTERNATIONAL JOURNAL OF CANCER, (20111015), vol. 129, no. 8, doi:10.1002/ijc.26145, ISSN 0020-7136, pages 2013 - 2024, XP055086969 [X] 1-16,19-23 * page 2016, column l; table 2 * [I] 1-23
INTERNATIONAL-SEARCH-REPORT- ROBINSON M K ET AL, "Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 99, no. 9, doi:10.1038/SJ.BJC.6604700, ISSN 0007-0920, (20081028), pages 1415 - 1425, (20081007), XP009115294 [I] 1-23 * page 1418, column r, paragraph 2; figure 1 * * page 1421, column r * * page 1419, column r, paragraph l *
INTERNATIONAL-SEARCH-REPORT- LU D ET AL, "Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (20040123), vol. 279, no. 4, doi:10.1074/JBC.M310132200, ISSN 0021-9258, pages 2856 - 2865, XP002316541 [Y] 1-23 * page 2861, column l *
INTERNATIONAL-SEARCH-REPORT- C. ROZAN ET AL, "Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting Fc RIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells", MOLECULAR CANCER THERAPEUTICS, (20130801), vol. 12, no. 8, doi:10.1158/1535-7163.MCT-12-1012, ISSN 1535-7163, pages 1481 - 1491, XP055156453 [X] 1-16,19-23 * page 1484, column r; figure 1a * * page 1489, column l, paragraph 2 *
OPPOSITION- Stevenson G T, "CD38 as a therapeutic target", Molecular Medicine,, (20060000), vol. 12, no. 11-12, pages 345 - 346, XP009145827-
OPPOSITION- Rob C Roovers; Maria J W D Vosjan; Toon Laeremans; Rachid El Khoulati; Renée C G De Bruin; Kathryn M Ferguson; Arie J Verkleij; Guus A M S Van Dongen; Paul M P Van Bergen En Henegouwen, "A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth", Int J Cancer, (20110000), vol. 129, pages 2013 - 2024, XP055086969
OPPOSITION- Robinson M K; Hodge K M; Horak E; Sundberg A L; Russeva M; Shaller C C; von Mehren M; Shchaveleva I; Simmons H H; Marks J D; Adams G P, "Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro", British Journal of Cancer,, (20080000), vol. 99, pages 1415 - 1425, XP009115294
OPPOSITION- ELS CONRATH K; ET AL, "Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs", J Biol Chem, (20010000), vol. 276, no. 10, pages 7346 - 7350, XP002248402
OPPOSITION- OLDENBORG P-A, "ROLE OF CD47 IN ERYTHROID CELLS AND IN AUTOIMMUNITY", Leuk Lymphoma, (20040000), vol. 45, no. 7, pages 1319 - 1327, XP008060559
OPPOSITION- MACKAY C R; ET AL, "EXPRESSION AND MODULATION OF CD44 VARIANT ISOFORMS IN HUMANS", The journal of cell biology,, (19940000), vol. 124, no. 1-2, pages 71 - 82, XP000471699
OPPOSITION- Danielle Naville; Adeline Duchampt; Michèle Vigier; Delphine Oursel; René Lessire; Hélène Poirier; Isabelle Niot; Martine Bégeot; Philippe Besnard; Gilles Mithieux, "Link between Intestinal CD36 Ligand Binding and Satiety Induced by a High Protein Diet in Mice", PloS one, (20120000), vol. 7, no. 1, page e30686, XP055513432
OPPOSITION- Mueller Dafne; Kontermann Roland E, "Bispecific Antibodies for Cancer Immunotherapy Current Perspectives", Biodrugs, (20100000), vol. 24, no. 2, pages 89 - 98, XP009164507
OPPOSITION- KONTERMANN ROLAND E, "Dual targeting strategies with bispecific antibodies", mAbs, (20120000), vol. 4, no. 2, pages 182 - 187, XP002698995

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents